F4 FundFund
TeamPortfolioRaiseEssays
Sign in
Investment ThesisInvestment TeamF4 Research BriefSelected PortfolioRecent UpdatesFrequent co-investorsSimilar Firms
Warm Fund

Ahren Innovation Capital

ahreninnovationcapital.com · London, UK

Investment thesis

Invest in deep technology at the intersection of ground-breaking science and high-end technology, backing founders from pre-seed to pre-IPO with patient and active capital.

Leads & Follows
Lead Tendency
01Investment Thesis

Invest in deep technology at the intersection of ground-breaking science and high-end technology, backing founders from pre-seed to pre-IPO with patient and active capital.

02Investment Team
AN
Alice Newcombe-Ellis
Founding & General Partner
PL
Peter Lourensz
Chief Financial Officer
PB
Peter Baines
Venture Partner
JG
Joanna Green
Partner
JM
Janusz Marecki
AI Partner
OH
Oliver Hedaux
Principal
AN
Anuj Nanwani
Principal
SC
Sabila Chilaeva
Associate
VK
Vera Kunz
Associate
PS
Phoebe Seltzer
Associate
SS
Sir Shankar Balasubramanian
Founding Partner
ZG
Zoubin Ghahramani
Founding Partner
SS
Sir Steve Jackson
Founding Partner
AP
Andy Parker
Founding Partner
SV
Sir Venki Ramakrishnan
Founding Partner
LM
Lord Martin Rees
Founding Partner
SG
Sir Gregory Winter
Founding Partner
RC
Roberto Cipolla
Science Partner
03F4 Research Brief

Ahren Innovation Capital Research

Investment Thesis

Ahren Innovation Capital is a London-based deep tech and deep science investor. It backs transformational companies at the intersection of ground-breaking science and high-end technology that will penetrate or create massive markets. The firm says it takes asymmetric, considered risk in pursuit of superior rewards, and wants its capital to have a positive impact on the world. Its tagline is "Investing in Deep Technology to Create the Unimaginable."

Ahren was founded in 2017 by Alice Newcombe-Ellis, formerly of TPG Capital and Lansdowne Partners, together with a group of senior Cambridge scientists who serve as Founding and Science Partners. These include Nobel laureates Sir Venki Ramakrishnan and Sir Gregory Winter, as well as Sir Shankar Balasubramanian, Sir Steve Jackson, Lord Martin Rees, Professor Andy Parker and Professor Zoubin Ghahramani. The firm says technologies created by its scientific partners are worth more than $100BN combined today. The Science Partners take part in sourcing, in deep-tech diligence and in supporting portfolio companies.

Sector Focus

Ahren names four broad domains of interest:

  • Brain & AI: machine learning, applied AI and AI hardware, for example AI21 Labs, Graphcore and Phaidra
  • Genetics & Platform Technologies: therapeutics platforms, genomics, cell reprogramming and engineering biology, for example Bicycle Therapeutics, Mogrify, Cellarity and Constructive Bio
  • Space & Robotics: robotics and automation, for example Ambi Robotics, Mentee Robotics and Micropsi Industries
  • Efficient Energy: climate and energy technology, for example Heirloom, Sunfire and Velocys

It also invests in quantum technology (Nu Quantum, Zapata AI) and food technology (New Culture, Zoe).

Stage Focus

Ahren partners with founders at all stages, from pre-seed to pre-IPO. It will help build companies from scratch or provide capital and expertise to high-growth businesses. It describes its capital as both patient and active.

Check Size

Ahren does not publish a check size.

Lead Tendency

The firm has led and co-led rounds. It led the 2018 seed round in Mogrify and the $30M round in Cambridge Epigenetix, co-led the Series A in Adrestia with GSK, and has also participated in rounds led by others, such as Zya's Series A.

Recent Activity

Ahren says it is investing from its latest fund and has more than $400M in dry powder. Its first fund closed at more than $250M in July 2019. In November 2025 Cassidy Bio launched with Ahren as an investor. Constructive Bio raised a $58M Series A in September 2024. Mentee Robotics, an Ahren portfolio company, was acquired by Mobileye. Adrestia was acquired by Insmed in August 2023, Graphcore by SoftBank, and 6D.ai by Niantic. Bicycle Therapeutics went public.

Portfolio Highlights

  • AI21 Labs, Ambi Robotics, Bitfount, Micropsi Industries and Phaidra in applied AI and robotics
  • Bicycle Therapeutics (IPO), Adrestia (acquired by Insmed), Cellarity, Mogrify, Constructive Bio, Edifice Health, Ovo Labs, Rubedo Life Sciences and Zoe in life sciences
  • Heirloom, Sunfire, Velocys and Switchback Systems in energy and engineering biology
  • Nu Quantum and Zapata AI in quantum

Team

  • Alice Newcombe-Ellis, Founding & General Partner
  • Peter Baines, Venture Partner (formerly General Partner at Advent Venture Partners)
  • Joanna Green, Partner (life sciences)
  • Janusz Marecki, AI Partner (formerly Lead Scientist at DeepMind)
  • Oliver Hedaux, Principal (applied AI, robotics, science and education)
  • Anuj Nanwani, Principal (planet and efficient energy, quantum)
  • Peter Lourensz, Chief Financial Officer
  • Associates: Sabila Chilaeva, Vera Kunz and Phoebe Seltzer
  • Founding Partners: Sir Shankar Balasubramanian, Zoubin Ghahramani, Sir Steve Jackson, Andy Parker, Sir Venki Ramakrishnan, Lord Martin Rees and Sir Gregory Winter
  • Science Partner: Roberto Cipolla
  • Advisor: David Novak, Co-President of Clayton Dubilier & Rice

Decision Process

Ahren operates as a partnership of investors and scientists. The investment team sources and leads deals, and Science Partners join deep-tech diligence. The firm does not publish its decision timeline.

Founder Preferences

Ahren looks for exceptional founders and teams with a big vision and science-led technology. It offers a commercial engine, unicorn-founder advisors and strategic LP partnerships that give portfolio companies access, expertise and sometimes customers. It says it acts with strong values and treats founders well.

Geographic Focus

Ahren is based in London and backs companies in Europe, Israel and North America. Many of its early companies came out of Cambridge and other UK research institutions.

04Selected Portfolio
Aerospace & Defense
Zapata AI
Biotech & Life Sciences
Adrestia Therapeutics·Bicycle Therapeutics·Cellarity·Mogrify·OutSee·Switchback Systems·biomodal·Ovo Labs·Rubedo Life Sciences·Cassidy Bio·Constructive Bio
Climate & Sustainability
Velocys
Enterprise Software
6D.AI·AI21 Labs·Phaidra·Nu Quantum
Food & Beverage
New Culture
Healthcare & Digital Health
Bitfount·Edifice Health·Pictura Bio·ZOE
Insurance
Sunfire
Legal & Regtech
Heirloom
Robotics & Automation
Ambi Robotics·Mentee Robotics·Micropsi Industries
Semiconductors & Hardware
Graphcore
Open the full portfolio→
05Recent Updates

Fresh signals from public announcements, essays, and portfolio activity.

See full activity (5) →
Cassidy Bio launched with Ahren among its investors to develop gene editing therapies.
INVESTMENT·sttinfo.fi
NOV 20, 2025
Constructive Bio secured a $58M Series A.
INVESTMENT·ahreninnovationcapital.com
SEP 24, 2024
Mentee Robotics unveiled MenteeBot, a humanoid robot integrating AI across operational layers.
MILESTONE·ahreninnovationcapital.com
APR 17, 2024
Portfolio company Adrestia was acquired by Insmed.
EXIT·ahreninnovationcapital.com
AUG 3, 2023
Closed its fund at more than $250M for deep tech and deep science investing.
NEW FUND·ahreninnovationcapital.com
JUL 1, 2019
06Frequent co-investors
AC
Amadeus Capital Partners
Both backed 3 of the same companies
Constructive Bio, Nu Quantum, Graphcore
1
10D
Both backed 2 of the same companies
Mentee Robotics, Cassidy Bio
BC
Balderton Capital
Both backed 2 of the same companies
ZOE, Graphcore
DL
Deeptech Labs
Both backed 2 of the same companies
Pictura Bio, Nu Quantum
IC
IQ Capital
Both backed 2 of the same companies
Pictura Bio, Nu Quantum
Find the investors for your round→
07Similar Firms
PV
Pillar VC
$100K – $10M · Pre-Seed · Seed
→
UC
Undeterred Capital
$500K – $1M · Pre-Seed · Seed
→
RC
Refactor Capital
$1M – $2M · Pre-Seed · Seed
→
HV
Horizons Ventures
$1M – $25M · Pre-Seed · Seed
→
CI
Cambridge Innovation Capital
Seed · Series A
→
Quick Reference
Stages
Pre-Seed · Seed · Series A · Series B · Growth
Decision
Partnership
Location
London, UK
Sector Focus
Biotech & Life SciencesSemiconductors & HardwareRobotics & AutomationEnergy & Power
Models
Deep TechDeep Science
Technology
AI/MLGeneticsRoboticsQuantumEfficient Energy
See all Biotech & Life Sciences investors →See all Semiconductors & Hardware investors →See all Robotics & Automation investors →
Visit ahreninnovationcapital.com ↗

See how Ahren Innovation Capital matches your startup

Get a personalized match report in minutes.

Get Your Match Report
Focus Areas
Biotech & Life SciencesSemiconductors & HardwareRobotics & AutomationEnergy & Power

See how Ahren Innovation Capital matches your startup

Get a personalized match report in minutes.

Get Your Match Report
Is this your firm? Claim your profile
F4 Intelligence Report · Last Researched November 21, 2026F4 Research Engine